Exploring the impact of SABA use in asthma
ICSs improve asthma outcomes even in the mildest disease and anti-inflammatory reliever therapy is the most effective treatment for worsening asthma
You will learn:
• Recent updates to international guidelines regarding the use of short-acting β2-agonists (SABAs) in patients with mild or moderate/severe asthma and the reasons underpinning these changes
• The association between regular SABA use and worsening asthma
• The evidence for using inhaled corticosteroids for improved asthma outcomes
• A global and South African perspective on SABA prescriptions and associated asthma-related clinical outcomes in patients with asthma.
To access this module, please register or login: